– UK, Bridgend – ReNeuron Group plc (LON: RENE), a UK-based leader in Stem Cell and Exosomes Technologies, today announced the appointment of Martin Walton to its Board as a Non-Executive Director, with immediate effect.
Concurrently, the company also announced the resignations of Dr. Tim Corn and Mark Evans from the Board, effective immediately.
“I would like to welcome Martin Walton to the ReNeuron Board as we look to re-focus the business. Martin, a former investment banker, has completed more than 25 transactions in the last 12 years as a principal or advisor which has included start-up and spin-out investments, pre-IPO and IPO funding; M&A and over $1bn in investment and co-investment capital. He is the co-founder of LSE-listed Arix Bioscience plc (LSE: ARIX) and his current roles include serving as CEO of Excalibur Medicines Ltd and a Board Member of the Liverpool Life Sciences Accelerator Partnership. He brings a wealth of relevant experience in the life sciences sector.” said Board Chairman, Iain Ross.
Following these changes, the Board now comprises:
- Iain Ross (Executive Chairman);
- Catherine Isted (CFO and Executive Director)
- Dr. Michael Owen (Independent Non-Executive Director);
- Barbara Staehelin (Independent Non-Executive Director);
- Martin Walton (Independent Non-Executive Director).
About ReNeuron
ReNeuron is a UK-based Proprietary Stem Cell based Exosome Technologies company, harnessing its unique stem cell technologies to develop ‘off the shelf’ treatments for diseases with significant unmet needs.
ReNeuron’s stem cell-derived proprietary Exosome Technology platform offers a delivery mechanism for a variety of payloads such as siRNA, mRNA, proteins, small molecules, and genes. The Company has a growing number of partner collaborations with Global Pharma, Biotech and academic partners in this fast-expanding area of scientific and commercial interest. ReNeuron also has the ability, through its conditionally immortalised induced pluripotent stem cell platform, to make allogeneic tissue cells of choice and has the potential to produce exosomes with tissue specific targeting ability.
The Company has out-licensed its CTX Programme for stroke disability and hRPC programme in retinitis pigmentosa to Fosun in China and is looking to out-license both these programmes in other territories.
For more information : https://www.reneuron.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.
